Different effects of heparin in males and females

Clinical and Investigative Medicine

Volumn 21, Issue 2, 1998, Pages 71-78

  Campbell, Norman R C ^a,b,c,e,f   Hull, Russell D ^a,e   Brant, Rollin ^e   Hogan, David B ^c,e   Pineo, Graham F ^d,e   Raskob, Gary E ^a,e  

^a Div of General Internal Medicine

^b Division of Nephrology

^c Division of Geriatrics

^d Division of Hematology

^e Department of Medicine ^*

^f UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL PROTOCOL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE PREDISPOSITION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SEX DIFFERENCE; TIME;

AGING; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; MALE; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDIES; SEX CHARACTERISTICS; THROMBOPHLEBITIS;

EID: 0031967309     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Hirsh J. Heparin. N Engl J Med 1991;324:1565-74.
2. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990;322:1260-4.
3. Walker AM, Jick H. Predictors of bleeding during heparin therapy. JAMA 1980;244:1209-12.
4. Jick H, Slone D, Borda IT, Shapiro S. Efficacy and toxicity of heparin in relation to age and sex. N Engl J Med 1968;279:284-6.
5. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:324-7.
6. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. Ann Intern Med 1993;119: 874-81.
7. Kniffin WD, Baron JA, Barrett J, et al. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1994;154:861-6.
8. Lilienfeld DE, Godbold JH, Burke GL, et al. Hospitalization and case fatality for pulmonary embolism in the twin cities: 1979-1984. Am Heart J 1990;120:392-5.
9. Gillum RF. Pulmonary embolism and thrombophlebitis in the United States, 1970-1985. Am Heart J 1987;114:1262-4.
10. Anderson FA, Wheeler HB, Golberry RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep venous thrombosis and pulmonary embolism. Arch Intern Med 1991;151:933-8.
11. Glazier RI, Crowell EB. Randomized prospective trial of continuous vs intermittent heparin therapy. JAMA 1976;236:1365-7.
12. Landefeld CS, Cook EF, Flatley M, et al. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987;82:703-13.
13. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993;95:315-28.
14. Mant MJ, O'Brien BD, Thong KL, et al. Haemorrhagic complications of heparin therapy. Lancet 1977;1:1133-5.
15. Salzman EW, Deykin D, Shapiro RM, Rosenberg R. Management of heparin therapy: controlled prospective trial. N Engl J Med 1975;292:1046-50.
16. Norman CS, Provan JL. Control and complications of intermittent heparin therapy. Surg Gynecol Obstet 1977;145:338-42.
17. Vieweg WVR, Piscatelli RL, Houser JJ, Proulx RA. Complications of intravenous administration of heparin in elderly women. JAMA 1970;213:1303-6.
18. Kernohan RJ, Todd C. Heparin therapy in thromboembolic disease. Lancet 1966;1:621-3.
19. Eaker ED, Chesebro JH, Sacks FM, et al. Cardiovascular disease in woman. Circulation 1993;88:1999-2009.
20. Kitler ME. Coronary disease: are there gender differences. Eur Heart J 1994;15:409-17.
21. Antman EM. Hirudin in acute myocardial infarction. Circulation 1994;90:1624-30.
22. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90: 1631-7.
23. Antman EM. Hirudin in acute myocardial infarction. Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9a trial. Circulation 1994;90:1624-30.
24. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the proximal-vein thrombosis. N Engl J Med 1986;315:1109-14.
25. Schmucker DL, Vesell ES. Underrepresentation of women in clinical trials. Clin Pharmacol Ther 1993;54:11-5.
26. Merkatz RB, Temple R, Sobel S, et al, for the Working Group on Women in Clinical Trials. Women in clinical trials of new drugs. N Engl J Med 1993;329:292-6.
27. Whitfield LR, Levy G. Relationship between concentration and anticoagulant effect of heparin in plasma of normal subjects: magnitude and predictability of interindividual differences. Clin Pharmacol Ther 1980;28:509-16.
28. Mungall D, Raskob G, Coleman R, et al. Pharmacokinetics and dynamics of heparin in patients with proximal vein thrombosis. J Clin Pharmacol 1989;29:896-900.
29. Whitfield LR, Schentag JJ, Levy G. Relationship between concentration and anticoagulant effect of heparin in plasma of hospitalized patients: magnitude and predictability of interindividual differences. Clin Pharmacol Ther 1982;32:503-16.
30. Cipolle RJ, Seifert RD, Neilan BA, et al. Heparin kinetics: variables related to disposition and dosage. Clin Pharmacol Ther 1981;28:387-93.
31. Granger CB, Califf RM, Hirsh J, et al, for the GUSTO Investigators. APTTs after thrombolysis and standard intravenous heparin are often low and correlate with body weight, age and sex: experience from the GUSTO trial (abstract). Circulation 1992;86:I258.
32. Campbell NRC, Hull RD, Brant R, et al. Aging and heparin related bleeding. Arch Intern Med 1996;156: 857-60.
33. Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992;152:1589-95.
34. Refn I, Vestergaard L. The titration of heparin with protamine. Scand J Clin Lab Invest 1954;6:284-7.
35. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993;118:104-8.
36. Zeger SL, Liang K-Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42:121-30.
37. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
38. Hirsh J. Relationship between dose, anticoagulant effect and the clinical efficacy and safety of heparin. In: Lane DA, Bjork I, Lindahl U, editors. Heparin and related polysaccharides. New York: Plenum Press: 1992. p. 283-95.
39. Watson TD, Tan CE, McConnell M, et al. Measurement and physiological significance of lipoprotein and hepatic lipase activities in preheparin plasma. Clin Chem 1995;41(3):405-12.
40. Kario K, Matsuo T, Kobayashi H. Heparin cofactor II deficiency in the elderly: comparison with antithrombin III. Thromb Res 1992;66:489-98.
41. Notelovitz M. Exercise, nutrition and the coagulation effects of estrogen replacement on cardiovascular health. Obstet Gynecol Clin North Am 1987;14:121-41.
42. Notelovitz M, Kitchens CS, Rappaport V, et al. Menopausal status associated with increased inhibition of blood coagulation. Am J Obst Gvnecol 1981;141: 149-52.
43. Zhou F, Hook T, Thompson JA, Hook M. Heparin protein interactions. In: Lane DA, Bjork I, Lindahl U, editors. Heparin and related polysaccharides. New York: Plenum Press; 1992. p. 141-53.
44. Yu BP. Platelets and blood clotting. In: Masoro EJ, Adelman RC, Roth GS, editors. CRC handbook of physiology in aging. Boca Raton (FL): CRC Press, 1981. p. 63-5.
45. Masoro EJ. Lean body mass. In: Masoro EJ, Adelman RC, Roth GS, editors. CRC handbook of physiology in aging. Boca Raton (FL): CRC Press; 1981. p. 413-4.
46. NIH/ADAMHA policy concerning inclusion of women in study populations. PT3, II:KW 1014002, 1014006. NIH Guide Grants Contracts 1990;19:18-9.
47. Kinney EL, Trautman J, Gold JA, et al. Underrepresentation of women in new drug trials. Ramifications and remedies. Ann Intern Med 1981;95:495-9.
48. Greenblatt DJ, Sellers EM, Shader RI. Drug disposition in old age. N Engl J Med 1982;306:1081-8.